Natco Pharma Ltd.
Fundamentals
- Market cap
- ₹16,186 cr
- P/E
- 11.41×
- ROE
- 24.79%
- Debt / equity
- 0.04
- Div yield
- 0.56%
- 52-week range
- 789.00 — 1226.80
Company snapshot
Natco Pharma Ltd.
Pharmaceuticals
₹17,547 cr
P/E 12.37×
Latest quarter · Mar 2026
Sales₹739 cr
Net profit₹233 cr
Op. margin+17.3%
EPS₹14.97
Strength & growth
Debt / equity0.04×
Current ratio5.59×
Sales CAGR+13.5%
EPS CAGR+23.3%
The timeline — 3 notes on Natco Pharma Ltd.
July 2026
- 18 Jul 26 · 4:50 PM IST Lead Lead · Mid cap
Natco gets tentative FDA nod for generic Lynparza; launch hinges on patent case
US FDA clears Natco's olaparib tablets as generic version of AstraZeneca's $1.4B cancer drug, but Paragraph IV litigation keeps commercial launch uncertain.
- 08 Jul 26 · 12:06 PM IST Lead Lead · M&A · Mid cap
Natco Pharma invests ₹1,400 cr in SA sub, hikes Adcock stake to 49%
Board approves two major capital commitments: a ₹1,400 cr infusion in its wholly owned subsidiary and a ₹1,069 cr acquisition of an additional 13.25% in Adcock Ingram, taking holding to 49%.